[ Inside the business ]

ABSI stock analysis

ABSI · Absci Corp

Services-commercial physical and biological research. Shrinking 20%.

Nothing unusual in its latest filings.

The future, in 7 questions

01 What's priced in?Not available

Needs today's sales, share count and price.

02 Is the wave rising?Foundation models (large language models) · 17×
'20'21'22'23'24'251353
#4 of 20 mentioning it
03 Will customers keep buying?Technology Development Revenue: 95% of sales
Technology Development Revenue 95%Everyone else
Prepaid $1MSales −20%, steady
04 Is it scarce?No
PricingBacklogPrepaidSell-outTight
05 More profit per sale?Not enough data
06 Can it fund itself?1.9 yrs of cash
05 yrs10+ yrs
Shares +24.1%/yrDebt $0
07 What could break it?1 to watch
  • Heavy dilution

From SEC filings, price and Radar. Not advice.

The record

Early signals

Growth speeding up.

Sales growth −82%, −46%, then −20% vs. a year ago.

What could go wrong

Red flags.

It has moved 2.4× the market. In the 2022 rate shock it fell 62% while the market fell 24%. Debt is covered by cash. 1 red flag in its filings.

Speculative check

Speculative.

Speculative: operating loss, cash flowing out of operations, under $1B in sales. Cash runway: 1.9 years.

What they sell

Not broken out.

The filings don't split revenue by product in structured data.

Where each dollar goes

Not available.

Cost lines aren't reported in a comparable form.

Its market

1.6× the economy.

The government expects its industry, scientific research and development services, to grow 3.1% a year to 2035, vs. 2.0% for the whole economy.

Market size and share

Your call.

There's no official size for its market. Enter one you trust to see its share, and slide to see what a bigger share would mean.

Life cycle

Introduction.

It uses cash, invests, and raises money to keep going.

Earnings quality

Can't score.

Not available: some of the eight inputs aren't in the company's structured filings (common for banks, insurers and companies without a cost of goods line).

Competitive advantage

0 of 5 years.

Returns beat its 13.1% cost of capital in 0 of the last 5 years.

Future bets

3243% on research.

$91M a year on R&D. −$0M on equipment and buildings.

All figures from Absci Corp's SEC filings (EDGAR) unless tagged otherwise. Educational only, not investment advice.